Skip to main content

Table 2 Hazard ratios and 95% confidence intervals of all-cause mortality by quartiles of serum uric acid variability (measured by CV)

From: Visit-to-visit variability of serum uric acid measurements and the risk of all-cause mortality in the general population

Variable Quartile 1 Quartile 2 Quartile 3 Quartile 4 Per-SD increase Ptrend
Overall
 No. of cases 592 (4.29) 606 (4.49) 689 (5.11) 841 (6.24)   
 Incidence ratea 6.71 (6.20–7.26) 6.84 (6.33–7.40) 7.81 (7.26–8.40) 8.19 (7.63–8.80)   
 Model 1 Reference 1.03 (0.93–1.16) 1.22 (1.10–1.36) 1.40 (1.26–1.56) 1.14 (1.10–1.18) < 0.0001
 Model 2 Reference 1.03 (0.92–1.15) 1.20 (1.08–1.34) 1.34 (1.20–1.49) 1.12 (1.08–1.16) < 0.0001
 Model 3 Reference 1.03 (0.92–1.15) 1.20 (1.08–1.34) 1.33 (1.20–1.49) 1.12 (1.08–1.15) < 0.0001
 Sensitivity analysisb Reference 1.00 (0.88–1.13) 1.15 (1.02–1.30) 1.25 (1.10–1.42) 1.10 (1.05–1.15) < 0.0001
 Sensitivity analysisc Reference 1.01 (0.89–1.14) 1.16 (1.03–1.31) 1.33 (1.18–1.49) 1.12 (1.07–1.16) < 0.0001
 Sensitivity analysisd Reference 1.03 (0.92–1.15) 1.19 (1.06–1.32) 1.30 (1.07–1.45) 1.10 (1.06–1.15) < 0.0001
Baseline SUA < 300 μmol/L
 No. of cases 301 (4.14) 311 (3.93) 371 (4.32) 450 (5.14)   
 Incidence ratea 6.02 (5.38–6.74) 5.71 (5.11–6.38) 6.29 (5.68–6.96) 7.51 (6.84–8.23)   
 Model 1 Reference 1.00 (0.85–1.17) 1.11 (0.96–1.30) 1.34 (1.16–1.55) 1.13 (1.07–1.19) < 0.0001
 Model 2 Reference 1.00 (0.85–1.17) 1.10 (0.95–1.29) 1.33 (1.14–1.54) 1.15 (1.08–1.22) < 0.0001
 Model 3 Reference 1.01 (0.86–1.19) 1.13 (0.97–1.31) 1.38 (1.18–1.61) 1.15 (1.08–1.21) < 0.0001
 Sensitivity analysisb Reference 1.01 (0.86–1.18) 1.12 (0.96–1.31) 1.31 (1.11–1.54) 1.13 (1.06–1.20) < 0.0001
 Sensitivity analysisc Reference 1.01 (0.89–1.14) 1.16 (1.03–1.31) 1.33 (1.18–1.49) 1.15 (1.08–1.22) < 0.0001
 Sensitivity analysisd Reference 0.99 (0.84–1.16) 1.10 (0.94–1.28) 1.31 (1.12–1.53) 1.13 (1.07–1.20) < 0.0001
Baseline SUA ≥ 300 μmol/L Reference 1.01 (0.85–1.20) 1.12 (0.95–1.32) 1.35 (1.14–1.60) 1.12 (1.06–1.20) < 0.0001
No. of cases 319 (5.12) 321 (5.75) 349 (7.12) 306 (6.45)   
Incidence ratea 7.52 (6.74–8.39) 8.48 (7.60–9.46) 10.50 (9.49–11.70) 9.47 (8.46–10.60)   
Model 1 Reference 1.07 (0.92–1.25) 1.36 (1.17–1.58) 1.48 (1.26–1.73) 1.14 (1.09–1.21) < 0.0001
Model 2 Reference 1.07 (0.92–1.25) 1.32 (1.14–1.54) 1.42 (1.21–1.67) 1.13 (1.06–1.20) < 0.0001
Model 3 Reference 1.08 (0.92–1.26) 1.32 (1.13–1.54) 1.42 (1.20–1.69) 1.12 (1.06–1.20) < 0.0001
Sensitivity analysisb Reference 1.04 (0.85–1.26) 1.42 (1.15–1.76) 1.64 (1.22–2.19) 1.18 (1.05–1.32) < 0.0001
Sensitivity analysisc Reference 1.02 (0.85–1.21) 1.24 (1.04–1.47) 1.42 (1.17–1.72) 1.13 (1.05–1.21) < 0.0001
Sensitivity analysisd Reference 1.07 (0.92–1.25) 1.32 (1.13–1.54) 1.38 (1.16–1.64) 1.12 (1.05–1.19) < 0.0001
  1. CV coefficient of variation, SD standard deviation
  2. Model 1 adjusted for age and gender
  3. Model 2 further adjusted for body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, education, income, smoking status, drinking status, physical activity, history of hypertension, diabetes, and dyslipidemia
  4. Model 3 further adjusted for antihypertensive agents, hypoglycemic agents, lipid-lowering agents, estimated glomerular filtration rate, high-sensitivity C-reactive protein, baseline serum uric acid, and mean serum uric acid
  5. aIncidence rate per 1000 person-years
  6. bSensitivity analysis was excluded the participants with a hyperuricemia event at baseline or in the follow-up period, and adjusted for variables in model 3
  7. cSensitivity analysis was excluded the participants with myocardial infarction or stroke event at baseline or in the follow-up period, and adjusted for variables in model 3
  8. dSensitivity analysis was adjusted for variables in model 3 plus variability of estimated glomerular filtration rate during 2006–2010